{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:49:01Z","timestamp":1789505341659,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":106,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sodium\u2013glucose co-transporter 2 inhibitors have become a cornerstone in managing chronic heart failure (CHF). While their acute impact on urinary glucose and sodium excretion is well-established, their mid- and long-term persistence of these effects remains uncertain. This study investigated fluid and sodium balance over 3\u2009months in a randomized, placebo-controlled trial (NCT03128528).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Overall, 74 patients with New York Heart Association class II\u2013III CHF and an ejection fraction (EF) \u226449% were randomized (2:1) to empagliflozin 10\u2009mg (n\u2009=\u200948) or placebo (n\u2009=\u200926). Sodium, potassium, glucose, urea, and urine were determined from standardized 24-h urine collections. Free water clearance (FWC) and plasma\/urine osmolality were calculated. Body weight was measured, and dedicated sodium magnetic resonance imaging (23Na-magnetic resonance imaging) was performed to quantify skin and muscle sodium levels at baseline, at 1\u2009month, and at 3\u2009months. Patients (mean age 66.4\u2009years; 84% male; EF 40%; baseline N-terminal pro-B-type natriuretic peptide 707.9\u2009pg\/ml) were followed up at 1 and 3\u2009months. Empagliflozin significantly increased natriuresis at 1\u2009month (p\u2009=\u20090.040), while natriuresis returned to baseline by 3\u2009months. Skin sodium content decreased at 1\u2009month (p\u2009=\u20090.039) and remained reduced at 3\u2009months (p\u2009=\u20090.013), while muscle sodium was unchanged. Persistent glucosuria (p\u2009&amp;lt;\u20090.001) increased urine osmolality at 3\u2009months (p\u2009=\u20090.003). Urine volume increased transiently at 1\u2009month (p\u2009=\u20090.046) but normalized by 3\u2009months. Empagliflozin-treated patients showed a reduction in FWC at 1 and 3\u2009months (p\u2009&amp;lt;\u20090.001), with a compensatory rise in copeptin levels, indicating increased vasopressin activity (1\u2009month: p\u2009=\u20090.020; 3\u2009months: p\u2009=\u20090.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mid-range effects of empagliflozin in heart failure with reduced EF include transient natriuresis and sustained glucosuria, with compensatory reductions in FWC. Reductions in skin sodium content were maintained, and volume homeostasis in CHF patients stabilized after 3\u2009months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.70078","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:16:28Z","timestamp":1762280188000},"page":"3134-3141","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Short- and Mid-Term Effects of Empagliflozin on Sodium Balance and Fluid Regulation in Chronic Heart Failure"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9650-9220","authenticated-orcid":false,"given":"Venera","family":"Bytyqi","sequence":"first","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU) , Erlangen ,","place":["Germany"]},{"name":"Department of Cardiology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Kannenkeril","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kolwelter","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Linz","sequence":"additional","affiliation":[{"name":"Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Bosch","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Striepe","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina V.","family":"Karg","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin M.","family":"Nagel","sequence":"additional","affiliation":[{"name":"Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Uder","sequence":"additional","affiliation":[{"name":"Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Achenbach","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E.","family":"Schmieder","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU) , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026021721514563100_ejhf70078-bib-0001","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0140-6736(14)61889-4","article-title":"The war against heart failure: The Lancet lecture","volume":"385","author":"Braunwald","year":"2015","journal-title":"Lancet"},{"key":"2026021721514563100_ejhf70078-bib-0002","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.carpath.2011.11.007","article-title":"The pathophysiology of heart failure","volume":"21","author":"Kemp","year":"2012","journal-title":"Cardiovasc Pathol"},{"key":"2026021721514563100_ejhf70078-bib-0003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021721514563100_ejhf70078-bib-0004","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021721514563100_ejhf70078-bib-0005","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamacardio.2023.0711","article-title":"Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the DELIVER trial","volume":"8","author":"Jhund","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026021721514563100_ejhf70078-bib-0006","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2026021721514563100_ejhf70078-bib-0007","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721514563100_ejhf70078-bib-0008","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026021721514563100_ejhf70078-bib-0009","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008365","article-title":"Enhanced expression and function of renal SGLT2 (sodium-glucose cotransporter 2) in heart failure: Role of renal nerves","volume":"14","author":"Katsurada","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026021721514563100_ejhf70078-bib-0010","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice","volume":"292","author":"Wang","year":"2017","journal-title":"J Biol Chem"},{"key":"2026021721514563100_ejhf70078-bib-0011","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"2026021721514563100_ejhf70078-bib-0012","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.117.029529","article-title":"Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus","volume":"136","author":"Striepe","year":"2017","journal-title":"Circulation"},{"key":"2026021721514563100_ejhf70078-bib-0013","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026021721514563100_ejhf70078-bib-0014","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-018-0385-5","article-title":"Empagliflozin induces transient diuresis without changing long-term overall fluid balance in Japanese patients with type 2 diabetes","volume":"9","author":"Yasui","year":"2018","journal-title":"Diabetes Ther"},{"key":"2026021721514563100_ejhf70078-bib-0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cmet.2020.06.014","article-title":"SGLT2 inhibitor: Not a traditional diuretic for heart failure","volume":"32","author":"Verma","year":"2020","journal-title":"Cell Metab"},{"key":"2026021721514563100_ejhf70078-bib-0016","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-023-01946-w","article-title":"Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure","volume":"22","author":"Packer","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026021721514563100_ejhf70078-bib-0017","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1111\/j.1751-7133.2010.00177.x","article-title":"Copeptin: A biomarker of cardiovascular and renal function","volume":"16","author":"Morgenthaler","year":"2010","journal-title":"Congest Heart Fail"},{"key":"2026021721514563100_ejhf70078-bib-0018","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/HYPERTENSIONAHA.111.00566","article-title":"23Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patients","volume":"61","author":"Kopp","year":"2013","journal-title":"Hypertension"},{"key":"2026021721514563100_ejhf70078-bib-0019","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2026021721514563100_ejhf70078-bib-0020","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"2026021721514563100_ejhf70078-bib-0021","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/MNH.0b013e32833aeb3b","article-title":"Sodium sensing in the interstitium and relationship to hypertension","volume":"19","author":"Titze","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026021721514563100_ejhf70078-bib-0022","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00392-022-02119-7","article-title":"The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: Results from a placebo-controlled randomised trial","volume":"112","author":"Kolwelter","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026021721514563100_ejhf70078-bib-0023","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1161\/01.HYP.31.5.1083","article-title":"Sodium induces hypertrophy of cultured myocardial myoblasts and vascular smooth muscle cells","volume":"31","author":"Gu","year":"1998","journal-title":"Hypertension"},{"key":"2026021721514563100_ejhf70078-bib-0024","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1681\/ASN.2016060662","article-title":"Skin sodium concentration correlates with left ventricular hypertrophy in CKD","volume":"28","author":"Schneider","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026021721514563100_ejhf70078-bib-0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000507272","article-title":"Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes","volume":"51","author":"Marathias","year":"2020","journal-title":"Am J Nephrol"},{"key":"2026021721514563100_ejhf70078-bib-0026","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-Reduced trial","volume":"77","author":"Packer","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026021721514563100_ejhf70078-bib-0027","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/dom.14729","article-title":"Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND","volume":"24","author":"Sen","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026021721514563100_ejhf70078-bib-0028","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/12\/3134\/66836235\/eurjhf_27_12_3134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/12\/3134\/66836235\/eurjhf_27_12_3134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:51:56Z","timestamp":1771383116000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/12\/3134\/8470654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.70078","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"2025-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}